142 related articles for article (PubMed ID: 10463941)
1. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP.
Feng JY; Shi J; Schinazi RF; Anderson KS
FASEB J; 1999 Sep; 13(12):1511-7. PubMed ID: 10463941
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
3. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.
Feng JY; Murakami E; Zorca SM; Johnson AA; Johnson KA; Schinazi RF; Furman PA; Anderson KS
Antimicrob Agents Chemother; 2004 Apr; 48(4):1300-6. PubMed ID: 15047533
[TBL] [Abstract][Full Text] [Related]
4. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
5. Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase.
Ray AS; Murakami E; Peterson CN; Shi J; Schinazi RF; Anderson KS
Antiviral Res; 2002 Dec; 56(3):189-205. PubMed ID: 12406504
[TBL] [Abstract][Full Text] [Related]
6. Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ.
Sohl CD; Szymanski MR; Mislak AC; Shumate CK; Amiralaei S; Schinazi RF; Anderson KS; Yin YW
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8596-601. PubMed ID: 26124101
[TBL] [Abstract][Full Text] [Related]
7. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
8. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Severini A; Liu XY; Wilson JS; Tyrrell DL
Antimicrob Agents Chemother; 1995 Jul; 39(7):1430-5. PubMed ID: 7492080
[TBL] [Abstract][Full Text] [Related]
10. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs.
Feng JY; Johnson AA; Johnson KA; Anderson KS
J Biol Chem; 2001 Jun; 276(26):23832-7. PubMed ID: 11328813
[TBL] [Abstract][Full Text] [Related]
11. Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Klarmann GJ; Smith RA; Schinazi RF; North TW; Preston BD
J Biol Chem; 2000 Jan; 275(1):359-66. PubMed ID: 10617626
[TBL] [Abstract][Full Text] [Related]
12. Elucidating molecular interactions of
Hung M; Tokarsky EJ; Lagpacan L; Zhang L; Suo Z; Lansdon EB
Commun Biol; 2019; 2():469. PubMed ID: 31872074
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
Balzarini J; Wedgwood O; Kruining J; Pelemans H; Heijtink R; De Clercq E; McGuigan C
Biochem Biophys Res Commun; 1996 Aug; 225(2):363-9. PubMed ID: 8753770
[TBL] [Abstract][Full Text] [Related]
14. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma.
Gray NM; Marr CL; Penn CR; Cameron JM; Bethell RC
Biochem Pharmacol; 1995 Sep; 50(7):1043-51. PubMed ID: 7575660
[TBL] [Abstract][Full Text] [Related]
15. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
16. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
17. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
18. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
19. The molecular basis of inhibition and toxicity of modified cytosine analogues targetting HIV-1 reverse transcriptase.
Anderson KS
Antivir Chem Chemother; 2001; 12 Suppl 1():13-7. PubMed ID: 11594679
[TBL] [Abstract][Full Text] [Related]
20. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
